Value of tofacitinib extended induction therapy in patients with moderate-to-severe ulcerative colitis: A real-world 52-week follow-up study

doi:10.3748/wjg.v31.i42.111282

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 42

This Article

(49)

(45)

(0)

(8)

(874)

(2)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastroenterol. Nov 14, 2025; 31(42): 111282
Published online Nov 14, 2025. doi: 10.3748/wjg.v31.i42.111282

Table 4 Factors associated with drug discontinuation at week 52

Factors	OR (95%CI)	P value
Age	1.040 (0.979-1.105)	0.208
Male sex	1.442 (0.319-6.529)	0.635
Montreal classification	1.400 (0.238-8.240)	0.710
Disease duration	1.012 (0.911-1.125)	0.819
Family history of IBD	NA
Current smoker	16.500 (1.353-201.290)	0.028^a
BMI	1.008 (0.883-1.150)	0.910
Extraintestinal manifestations	2.400 (0.500-11.519)	0.274
Active extraintestinal manifestation	4.167 (0.667-26.017)	0.127
Previous treatment	0.960 (0.087-10.573)	0.973
Number of previous treatments	0.866 (0.445-1.687)	0.673
Partial Mayo	1.193 (0.779-1.827)	0.417
CRP	1.056 (0.985-1.132)	0.127
Albumin	0.553 (0.141-2.159)	0.394
Hb	1.155 (0.730-1.829)	0.538
PLT	1.001 (0.994-1.007)	0.854
WBC	1.000 (1.000-1.000)	0.857
Gran	1.000 (1.000-1.001)	0.224
Endoscopic Mayo	1.290 (0.343-4.848)	0.706
Full Mayo score	1.385 (0.835-2.297)	0.207

^aP < 0.05.

IBD: Inflammatory bowel disease; BMI: Body mass index; CRP: C-reactive protein; Hb: Hemoglobin; PLT: Platelets; WBC: White blood counts; Gran: Granulocytes; CI: Confidence interval; NA: Not available; OR: Odds ratio.

Full Size Table

Citation: Tzouvala M, Zacharopoulou E, Kalafateli M, Viazis N, Psistakis A, Theodoropoulou A, Drygiannakis I, Karmiris K, Koutroubakis IE, Kevrekidou P, Soufleris K, Katsaros M, Giouleme O, Fousekis F, Katsanos K, Christodoulou D, Gaki A, Papathanasiou E, Bamias G, Zampeli E, Michopoulos S, Kyriakos N, Veretanos C, Argyriou K, Kapsoritakis A, Tribonias G, Mantzaris GJ, Liatsos C. Value of tofacitinib extended induction therapy in patients with moderate-to-severe ulcerative colitis: A real-world 52-week follow-up study. World J Gastroenterol 2025; 31(42): 111282
URL: https://www.wjgnet.com/1007-9327/full/v31/i42/111282.htm
DOI: https://dx.doi.org/10.3748/wjg.v31.i42.111282

Tzouvala M, Zacharopoulou E, Kalafateli M, Viazis N, Psistakis A, Theodoropoulou A, Drygiannakis I, Karmiris K, Koutroubakis IE, Kevrekidou P, Soufleris K, Katsaros M, Giouleme O, Fousekis F, Katsanos K, Christodoulou D, Gaki A, Papathanasiou E, Bamias G, Zampeli E, Michopoulos S, Kyriakos N, Veretanos C, Argyriou K, Kapsoritakis A, Tribonias G, Mantzaris GJ, Liatsos C. Value of tofacitinib extended induction therapy in patients with moderate-to-severe ulcerative colitis: A real-world 52-week follow-up study. World J Gastroenterol 2025; 31(42): 111282 [PMID: 41278164 DOI: 10.3748/wjg.v31.i42.111282]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.